分子分型对低危和中危子宫内膜癌预后及复发模式的影响
这项回顾性队列研究纳入2006—2017年挪威镭医院的626例低/中危子宫内膜癌患者,610例可分子分型。中位随访8.9年后,各分子组无复发生存时间与癌特异性生存差异有统计学意义,p53异常组预后差且复发多为腹主动脉旁/远处转移,POLE突变组预后极佳。
要点
- 低/中危子宫内膜癌分子分型:POLE突变9%、MMRd 33%、p53异常6%、NSMP 52%。
- p53异常组预后差,12例复发中10例为腹主动脉旁/远处转移。
- POLE突变组预后极佳;NSMP组L1CAM表达与更短癌特异性生存相关。
核心结论
- 分子分型组间结局差异由复发频率和复发模式差异驱动,低/中危子宫内膜癌患者也需更高诊断精度。
- 作者认为,辅助治疗策略需考虑对p53异常肿瘤行全身治疗、对POLE突变肿瘤降阶梯治疗。
研究设计与样本
- 回顾性队列研究,纳入2006—2017年挪威镭医院(奥斯陆大学医院)收治的低/中危子宫内膜癌患者。
- 626例患者中610例可完成分子分型,分为POLE突变、错配修复缺陷(MMRd)、p53异常和无特定分子分型(NSMP)四组。
- 主要结局为至复发时间和癌特异性生存。
主要发现
- 610例可分子分型患者中,POLE突变57例(9%)、MMRd 202例(33%)、p53异常34例(6%)、NSMP 317例(52%)。
- 中位随访8.9年后,各分子组间至复发时间和癌特异性生存差异有统计学意义。
- p53异常组预后差,12例复发患者中10例表现为腹主动脉旁/远处转移。
- POLE突变组预后极佳。
- NSMP组中L1CAM表达与更短癌特异性生存相关,但与至复发时间无关。
临床怎么用
- 作者认为,辅助治疗策略需考虑对p53异常肿瘤行全身治疗、对POLE突变肿瘤降阶梯治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The role of molecular classification in patients with low/intermediate risk endometrial cancer (EC) is uncertain. Higher precision in diagnostics will inform the unsettled debate on optimal adjuvant treatment. We aimed to determine the association of molecular profiling with patterns of relapse and survival. MATERIAL AND METHODS: This retrospective cohort study included patients referred to The Norwegian Radium Hospital, Oslo University Hospital from 2006-2017. Patients with low/intermediate risk EC were molecularly classified as pathogenic polymerase epsilon (POLE)-mutated, mismatch repair deficient (MMRd), p53 abnormal, or no specific molecular profile (NSMP). The main outcomes were time to recurrence (TTR) and cancer-specific survival (CSS). RESULTS: Of 626 patients, 610 could be molecularly classified. Fifty-seven patients (9%) had POLE-mutated tumors, 202 (33%) had MMRd tumors, 34 (6%) had p53 abnormal tumors and 317 (52%) had NSMP tumors. After median follow-up time of 8.9 years, there was a statistically significant difference in TTR and CSS by molecular groups. Patients with p53 abnormal tumors had poor prognosis, with 10 of the 12 patients with relapse presenting with para-aortic/distant metastases. Patients with POLE mutations had excellent prognosis. In the NSMP group, L1CAM expression was associated with shorter CSS but not TTR. CONCLUSIONS: The differences in outcome by molecular groups are driven by differences in relapse frequency and -patterns and demand a higher precision in diagnostics, also in patients with low/intermediate risk EC. Tailored adjuvant treatment strategies need to consider systemic treatment for patients with p53 abnormal tumors and de-escalated treatment for patients with POLE mutated tumors.
引用
- Lindemann K, Kildal W, Kleppe A, et al. Impact of molecular profile on prognosis and relapse pattern in low and intermediate risk endometrial cancer. Eur J Cancer. 2024. PMID: 38330767. doi:10.1016/j.ejca.2024.113584
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。